Observing the effects of kidney cancer surgery on patients
Official title: 2007 - Rene: Observational Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent Radical Nefrectomy/Tumorectomy Surgery
Run by IRCCS San Raffaele · NCT06147349 · Data updated 2026-11-12
This study looks at how kidney cancer surgery affects patients over time to see how it impacts their quality of life and chances of relapse.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milan, MI) |
| Status | Recruiting |
| Started | January 27, 2010 |
| Main results expected | February 4, 2028 |
| Study ends | February 4, 2028 |
| Registry record updated | November 27, 2023 |
| Trial ID | NCT06147349 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with kidney cancer who are scheduled for surgical intervention.
✕Probably not a fit
Patients under 18 years old or those without a kidney cancer diagnosis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect clinical data from patients who have undergone radical or partial nephrectomy for kidney cancer. Participants will be followed for approximately 10 years, with regular visits and questionnaires to assess their quality of life and monitor for potential relapses. Data will be gathered through an electronic case report form, ensuring adherence to strict privacy and good clinical practice standards. The study seeks to enhance scientific understanding of renal cancer and improve future treatment strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved management and outcomes for patients with kidney cancer.
How similar studies have gone: Other observational studies have shown success in understanding the long-term effects of cancer surgeries, making this approach both relevant and valuable.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older * Kidney cancer diagnosis * Indication to cancer removal through surgery * Ability to read and sign the informed consent Exclusion Criteria: * Age \< 18 years * Absence of kidney cancer * Inability to read and sign the informed consent
Where it's running
-
IRCCS Ospedale San Raffaele
Milan, Mi, Italy Recruiting
Study contacts
- Principal investigator: Francesco Montorsi, MD — IRCCS Ospedale San Raffaele
- Study coordinator: Francesco Montorsi, MD.
- Email: montorsi.francesco@hsr.it
- Phone: 02 2643 7286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
Hospital admissions for blood in the urine
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Spectral CT during embolization and ablation for liver and kidney tumors
This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.
-
Image-guided stereotactic body radiotherapy for primary kidney cancer (STONE)
This will try high-dose, focused radiation (SBRT) to treat adults with a single small primary kidney cancer who are not good candidates for surgery or who decline surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.